Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

NCT02383238 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG: Dapagliflozin
DRUG: Placebo

Sponsor

University of Erlangen-Nürnberg Medical School